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Compare respiratory health in children born extremely preterm (EP) or with extremely low
birthweight (ELBW) nearly one decade apart, hypothesizing that better perinatal manage-
ment has led to better outcome.
Design
Fifty-seven (93%) of 61 eligible 11-year old children born in Western Norway in 1999–2000
with gestational age (GA) <28 weeks or birthweight <1000 gram (EP1999–2000) and matched
term-controls were assessed with comprehensive lung function tests and standardized
questionnaires. Outcome was compared with data obtained at 10 years of age from all (n =
35) subjects born at GA <29 weeks or birthweight <1001 gram within a part of the same
region in 1991–92 (EP1991–1992) and their matched term-controls.
Results
EP1999–2000 had significantly reduced forced expiratory flow in 1 second (FEV1), FEV1 to
forced vital capacity (FEV1/FVC) and forced expiratory flow between 25–75% of FVC
(FEF25–75), with z-scores respectively -0.34, -0.50 and -0.61 below those of the term-control
group, and more bronchial hyperresponsiveness to methacholine (dose-response-slope
13.2 vs. 3.5; p<0.001), whereas other outcomes did not differ. Low birthweight z-scores, but
not neonatal bronchopulmonary dysplasia (BPD) or low GA, predicted poor outcome. For
children with neonatal BPD, important lung-function variables were better in EP1999–2000
compared to EP1991–1992. In regression models, improvements were related to more use of
antenatal corticosteroids and surfactant treatment in the EP1999–2000.
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Conclusions
Small airway obstruction and bronchial hyperresponsiveness were still present in children
born preterm in 1999–2000, but outcome was better than for children born similarly preterm
in 1991–92, particularly after neonatal BPD. The findings suggest that better neonatal man-
agement not only improves survival, but also long-term pulmonary outcome.
Introduction
Since the 1990s most infants born extremely preterm or with extremely low birthweight (here-
after referred to as EP-born) in high-income countries have survived to discharge [1, 2]. Birth
at this stage of pregnancy implies that gas exchange must take place in fetal lungs, often leading
to the syndrome of bronchopulmonary dysplasia (BPD) [3]. Life-long pulmonary prospects
after EP birth and BPD are unknown, and concerns have been expressed for future functional
deficits, such as early onset respiratory insufficiency [4, 5].
Neonatal pulmonary autopsy data suggest that EP birth may lead to severe bronchoalveolar
abnormalities, but structural data from later life are scarce [6]. However, a range of functional
abnormalities have repeatedly been described in EP-born survivors, such as airway obstruction,
bronchial hyperresponsiveness, pulmonary hyperinflation and impaired gas diffusing capacity.
Generally, those with neonatal BPD do worse. This scenario applies to EP-born adults from the
early era of neonatal intensive care units (NICUs) as well as to children exposed to the far more
advanced treatments introduced in the 1990s [7–12]. As lung function seems to track from
childhood to adulthood [9, 13, 14], early onset chronic obstructive pulmonary disease (COPD)
is a feared scenario in high-risk subgroups [4, 5].
Better NICU management benefits all infants born preterm, but it also facilitates survival of
more immature and vulnerable individuals who may be at particular risk of severe long-term
morbidity [2, 15]. Therefore, respiratory health and lung function after EP birth have been
closely monitored in population-based controlled longitudinal studies in Western Norway
since the 1980s [13, 16]. With the present study, we aimed to address respiratory outcomes at
11 years of age in our most recent cohort born EP in 1999–2000 (EP1999–2000) and to compare
the findings with those of children born similarly preterm in 1991–1992 (EP1991–1992). We
hypothesized that changes in perinatal care during the 1990s were associated with respiratory
improvements [16, 17].
Materials and Methods
Detailed descriptions are provided in S1 File, and the inclusion process is visualized in Fig 1.
Subjects, definitions and neonatal background data
The EP1999–2000 included all NICU admitted infants born in 1999–2000 with gestational age
(GA)<28 weeks or birth weight (BW)<1000 gram within Western Norway Health Authority,
which serves a population of approximately 1.1 million. It was a regional selection of a national
cohort [2]. The infants were treated at one of the two regional NICUs (Bergen and Stavanger).
The EP1999–2000 data were compared with data obtained at 10 years of age from all (n = 35) sub-
jects born with GA<29 weeks or BW<1001 gram within a part of the same region (popula-
tion 615 000) in 1991–92 and treated at the NICU in Bergen (EP1991–1992). EP1991–1992 data
have been published previously in a different context [13, 16] and relevant data are included in
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CPAP, continuous positive airway pressure; DLCO,
lung diffusion capacity for carbon monoxide; DRS,
dose-response-slope; EP, preterm born participants
of the present study; ERS, European Respiratory
Society; FENO, fractional exhaled nitric oxide; FEV1,
forced expiratory volume in 1 second; FEF25–75,
forced expiratory flow between 25 and 75% of vital
capacity; FRC, functional residual capacity; FVC,
forced vital capacity; GA, gestational age; Hb,
haemoglobin; JawNO, bronchial flux of NO; KCO,
diffusion capacity corrected for alveolar volume; NEC,
necrotizing enterocolitis; NICU, neonatal intensive
care unit; PDA, persistent ductus arteriosus; PD20,
the dose methacholine required to lower FEV1
20% of baseline level; Raw, airway resistance; ROP,
retinopathy of prematurity; RV, residual volume; SGA,
small for gestational age; SPT, skin prick test; TLC,
total lung capacity; VA, alveolar volume.
Fig 1. The recruitment of subjects in two cohorts of premature (EP) andmatched term-born subjects, one cohort born in 1991–92 and examined in
2001–2002, and one cohort born in 1999–2000 and examined in 2010–2012.
doi:10.1371/journal.pone.0144243.g001
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the present paper. The acronym ‘EP-born’ is used in this article to represent participants born
preterm in both inclusion periods.
For each EP-born participant of both birth-cohorts, the next-born child in the same mater-
nity ward of the same gender with GA>37 weeks and BW>3000 grams were identified from
birth protocols and invited as control. If that individual declined, the next-born eligible child
was invited until a match was obtained. Background data were extracted from compulsory
notifications to the Medical Birth Registry of Norway, registration-forms developed for the
study and questionnaires completed by the parents, including the International Study on
Asthma and Allergy in Childhood (ISAAC) questionnaire [18]. Small for gestational age
(SGA) was defined as BW<10th percentile for GA according to Norwegian growth curves
[19]. Z-scores for BW and later anthropometric measures were calculated with reference to
Norwegian growth curves [19, 20]. BPD was defined as still dependent on oxygen supplemen-
tation at 36 weeks’ postmenstrual age [3]. Oxygen supplementation was given according to
similar department policy in the two inclusion periods in the two participating NICUs, and at
36 weeks’ GA it was generally provided through low flow nasal cannulas guided by pulse oxim-
etry targeting 90–95% saturation. Important changes of treatment between the two inclusion
periods were more extensive use of surfactant and antenatal corticosteroids and a change from
synthetic (Exosurf1) (31) to natural surfactant (Curosurf1) (Table 1) (32, 33). Most areas of
neonatal intensive care medicine had gone through refinements, such as better standardization
of antenatal and perinatal care, a higher level of competence among neonatologists and nurses
regarding the special needs of these vulnerable infants, and better exploitation of technological
advances, such as patient coordinated assisted ventilation and various forms of oscillation.
The studies were approved by the regional committee on medical research ethics in Western
Norway Health Authority (RECWest), and parents of all participants gave written consent.
Measurements
The two birth-cohorts were examined at 10–11 years of age in 2001–2002 and 2010–2012,
respectively, using the same type of equipment and the same examination program, except that
nitric oxide was not studied in EP1991–1992. The children were seen on two separate days at the
University Hospitals in Bergen or Stavanger according to place of birth. Spirometry, static lung
volumes and pulmonary diffusing capacity for carbon monoxide (DLCO/KCO) were measured
with Vmax equipment (SensorMedics Inc, Anaheim, USA), applying standard quality criteria
[21, 22] with data standardized for age, height and gender [23, 24], except KCO reported as raw
data. Fractional exhaled nitric oxide (FeNO) was measured with Exhalyzer CLD-88 (EcoMedics,
Switzerland), according to ATS/ERS recommendations [25]. Alveolar NO (ppb) (CANO) and
bronchial flux of NO (nl/sec) (Jaw NO) were calculated using three different flows (30, 100 and
300 ml/sec) [26]. Methacholine provocation was performed with an inhalation-synchronised
dosimetric nebulizer (Spira Electra, Finland), providing baseline FEV1 65% predicted [27,
28]. The test continued until a fall of 20% or more compared to baseline FEV1, or until the
maximum dose of 11.5 μmol methacholine. Dose-response slope (DRS) was calculated as the
ratio of maximum percentage decline in FEV1 from baseline to cumulative administered dose
of methacholine (%/μmol) [29]. Reversibility to salbutamol was assessed by measuring FEV1
before (baseline) and 10–15 minutes after administering 0.1 mg/10 kg salbutamol (Ventoline)
from a metered dose inhaler via a spacer (Volumatic); an increase12% was considered posi-
tive response [30]. Methacholine provocation and salbutamol reversibility tests were done on
separate days.
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Table 1. Perinatal data comparing children born preterm in 1991–92 (EP1991–92) and in 1999–2000 (EP1999–2000).
EP1991–92 cohort EP1999–2000 cohort p-value
a
Subjects; n (%) Control 35 54
All EP 35 57
- non BPD 23 (66) 26 (46) 0.067
- BPD 12 (34) 31 (54)
Female gender;n (%) Control 22 (63) 25 (46) 0.135
All EP 22 (63) 28 (49) 0.209
- non BPD 17 (74) 16 (62) 0.379
- BPD 5 (42) 12 (39) 0.860
Birthweight, gram; mean (SD) Control 3564 (275) 3701 (434) 0.073
All EP 933 (204) 850 (175) 0.039
- non BPD 976 (195) 873 (200) 0.073
- BPD 851 (203) 831 (151) 0.722
Birthweight; sds- score All EP -0.36 (0.9) -0.80 (1.3) 0.054
- non BPD -0.37 (0.9) -0.97 (1.4) 0.076
- BPD -0.32 (0.9) -0.66 (1.2) 0.386
Gestational age, weeks; mean (SD) All EP 26.7 (1.7) 26.8 (1.6) 0.974
- non BPD 27.2 (1.7) 27.3 (1.6) 0.788
- BPD 25.8 (1.5)* 26.3 (1.4)** 0.381
Small for gestational age (SGA); n (%) All EP 5 (14) 20 (35) 0.030
- non BPD 3 (13) 12 (46) 0.015
- BPD 2 (17) 8 (26) 0.570
Postnatal days with oxygen treatment; median (range) All EP 49 (2–180) 65 (0–250) 0.109
- non BPD 34 (2–70) 44 (0–78) 0.254
- BPD 92 (61–180) 79 (44–250) 0.080
Ventilator days; median (range) All EP 4.0 (0–55) 5.0 (0–24) 0.618
- non BPD 1.3 (0–40) 2.5 (0–21) 0.212
- BPD 12.7 (2–55)*** 8.0 (0–24)*** 0.011
Antenatal corticosteroids; n (%) All EP 15/34 (44) 46 (81) <0.001
- non BPD 11 (48) 21 (81) 0.005
- BPD 4/11 (36) 25 (81) 0.012
Surfactant; n (%) All EP 17 (49) 49/56 (88) <0.001
- non BPD 7 (30) 20/25 (80) 0.001
- BPD 10 (83) 29 (94) 0.367
Postnatal corticosteroids; n (%) All EP 10 (29) 18 (32) 0.772
- non BPD 2 (9) 1 (4) 0.549
- BPD 8 (67) 17 (55)*** 0.510
Closing of PDA; n (%) All EP 17 (49) 13 (23) 0.013
- non BPD 7 (30) 3 (12) 0.122
- BPD 10 (83) 10 (32) 0.004
Maternal smoking in pregnancy; n (%) Control 9 (26) - -
All EP 13 (37) 13/52 (25) 0.205
- non BPD 10 (43) 5/24 (21) 0.111
- BPD 3 (25) 8/28 (29) 0.957
Figures are means (SD), medians (ranges) or counts (%).
a The p-value denotes differences between those born in 1991–92 and in 1999–2000.
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Statistical analysis
Non-paired groups were compared using independent sample t-tests, Mann-Whitney U-test,
Fishers exact 2-sided mid-p value [31] or odds ratios (OR), and paired data with the mixed lin-
ear model (MLM) of SPSS, as appropriate. For EP1999–2000, multiple backward regression mod-
els were constructed in order to address potential associations between neonatal data and
selected background data (listed in the Results chapter) vs. current FEV1. Independent vari-
ables were included if the correlation with the dependent variable was> 0.3 and the bivariate
correlation with other independent variables was< 0.7. Interaction terms were used to test if
effects (differences in lung function between EP-born and matched term-controls) differed
between EP-born subgroups; i.e. BPD vs. non BPD, GA-categories (GA25 vs. 26–27 vs.28
weeks) and birth-cohort (1991–1992 vs. 1999–2000). The interaction terms were tested for
influence from selected neonatal factors that varied between the two preterm born cohorts (see
Results). Providing 60 cases were included, the study had 80% power to detect a difference in z-
FEV1 of 0.5 between EP1999–2000 and matched term-controls, given a two-sided significance
level of 0.05. SPSS (version 21.0) was used for computations.
Results
Subjects (Fig 1)
In EP1999–2000, 61 eligible EP-born were discharged alive, two could not be traced and two were
excluded due to cerebral palsy, leaving 57 (93%) participants, all but three Caucasians. In
EP1991–1992, all 35 eligible EP-born survivors participated, all Caucasians. On average, respec-
tively 1.6 and 1.3 term-born subjects were approached to recruit a full 1:1 control group for the
two inclusion periods. In EP1999–2000, uneven drop-outs eventually caused a numeric gender
difference; i.e., 49% EP-born vs. 46% controls were female (p = 0.85).
Perinatal data (Table 1)
For subjects admitted to the NICU, survival rates were 81% (EP1999–2000) vs. 74% (EP1991–92)
(p = 0.57). Due to slight differences in the inclusion criteria, mean BW was lower and the pro-
portion born SGA was higher in EP1999–2000. Eleven subjects (19%) were included solely by BW
(i.e. GA28 weeks) in EP1999–2000 (mean GA (range) 29.2 (28–31) weeks), and two solely by
BW (i.e. GA29 weeks) in EP1991–92 (GA 30 and 31 weeks). The number of participants born
at GA27 weeks was 46/57 (81%) and 21/35 (60%), respectively. For subjects with BPD in
EP1999–2000 compared to EP1991–1992, mean GA and BW did not differ, but days on ventilator
were fewer, a higher proportion had received prenatal corticosteroids and surfactant treatment
and fewer had artificial closure of persistent ductus arteriosus (surgery or indomethacin).
Anthropometric data and respiratory symptoms (Table 2)
At follow-up, EP1999–2000 was one year older than EP1991–1992. Anthropometric measures were
similar except that the control children for EP1999–2000 had slightly lower BMI. The prevalence
of ever having been diagnosed with asthma was similar for the two preterm-born cohorts, and
the proportion was significantly higher than for their respective term-born groups. Current
respiratory symptoms (wheezing) and use of asthma medication tended to be rarer in EP1999–
2000 than in EP1991–92 and not significantly different from term-controls, contrasting EP1991–92.
Wheeze was unrelated to airflow-limitation, with one report of current wheeze in the overall 15
subjects with z-FEV1 below -1.64, which is the lower limit of normal [23].
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Lung function for EP1999–2000
Data on EP1991–1992 have been published previously [13, 16], and relevant data are presented in
Table C in S1 File. For EP1999–2000, data are presented in Tables 3 and 4 and Table D in S1 File.
Flow-volume loops were satisfactorily obtained from all participants. Failure rates were minor
also for most other lung function tests, except measures of nitric oxide and lung diffusion (12–
14 of 57). The failure rates were similar for EP-born and term-controls on the individual tests;
details are presented in S1 File. EP-born had lower z-scores for FEV1, FEV1/FVC and FEF25–75,
higher airway resistance (Raw), and higher DRS from the methacholine challenge than term-
Table 2. Anthropometric data and respiratory symptoms at age 11 comparing children born preterm in 1991–92 (EP1991–92) and in 1999–2000
(EP1999–2000).
EP1991–92 cohort n = 35 EP1999–2000 cohort n = 57 p-value
a
Age; years Control 10.6 (0.4) 11.7 (0.7) <0.005
All EP 10.4 (0.4) 11.4 (0.6) <0.005
- non BPD 10.4 (0.5) 11.4 (0.6) <0.005
- BPD 10.4 (0.4) 11.5 (0.6) <0.005
Height; z-score Control 0.02 (0.9) 0.00 (1.1) 0.925
All EP -0.51 (1.2)* -0.41 (1.0)* 0.654
- non BPD -0.52 (1.3) -0.38 (1.0) 0.658
- BPD -0.49 (1.1) -0.43 (1.1)) 0.868
Weight; z-score Control 0.17 (1.0) -0.14 (1.1) 0.153
All EP -0.48 (1.4)* -0.33 (1.05) 0.570
- non BPD -0.40 (1.7) -0.43 (1.0) 0.956
- BPD -0.61 (0.8) -0.25 (1.1)) 0.303
BMI; z-score Control 0.25 (0.9) -0.22 (1.0) 0.033
All EP -0.28 (1.4) -0.16 (1.0) 0.644
- non BPD -0.18 (1.6) -0.35 (1.1) 0.660
- BPD -0.46 (0.9) 0.00 (1.0) 0.178
Asthma ever Control 3 (9) 5 (9) 0.933
All EP 12 (34)* 15 (26)* 0.427
- non BPD 6 (26) 5 (19) 0.587
- BPD 6 (50) 10 (32) 0.309
Asthma medication last 12 months Control 1 (3) 3 (6) 0.838
All EP 5 (14) 4 (7) 0.075
- non BPD 1 (4) 3 (12) 0.775
- BPD 4 (33) 1 (3) 0.006
Wheeze last 12 months Control 2 (6) 5 (9) 0.587
All EP 11 (31)* 8 (14) 0.055
- non BPD 6 (26) 4 (15) 0.383
- BPD 5 (42) 4 (13) 0.060
Atopy Control 8 (23) 20/50 (40) 0.105
All EP 9 (26) 12/55 (22) 0.675
- non BPD 8 (35) 6/25 (24) 0.435
- BPD 1 (8) 6/30 (20) 0.415
Figures are means (SD), medians (ranges) or counts (%).
a The p-value denotes differences between those born on 1991–92 and in 1999–2000.
* P-values for group differences between term controls vs. all EP within each cohort, * p<0.05. Atopy registered as minimum one positive SPT (skin prick
test) or IgE test in the EP1991–92 cohort and as minimum one positive SPT in the EP1999–2000 cohort.
doi:10.1371/journal.pone.0144243.t002
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Figures are observed means (95% confidence intervals), unless otherwise stated. For abbreviations, please see list. Lung diffusion data reported as %
predicted and as raw-data, and nitric oxide (NO) data only as raw-data, due to suboptimal reference equations for children.
* Interaction terms testing differences between EP and matched term-born controls in the group with BPD vs. without BPD were non-significant for all
variables, and therefore only the p-values for all EP vs. term-born controls were reported.
a Reversibility is given as percentage change in FEV1 after vs. before administration of beta agonist, assuming the pre-value is baseline.
b DRS is the ratio of maximum percentage decline in FEV1 from baseline to cumulative administered dose (μmol) of methacholine (%/μmol), reported as
geometric means due to a highly skewed distribution.
doi:10.1371/journal.pone.0144243.t003
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controls. DRS was negatively and similarly associated with z-FEV1 (p<0.001) in the EP- and
term-born groups (test of interaction, p = 0.21). Static lung volumes (z-TLC, z-FRC, z-RV and
RV/TLC), FeNO and DLCO did not differ significantly between the EP-born and term-born
groups. Nine subjects (7 EP-born; 5 BPD and 2 non-BPD, and 2 term-born) had12%
increase in FEV1 on the salbutamol reversibility test (EP vs. term-born, p = 0.18). Mean FEV1
change before vs. after salbutamol did not differ between those born EP and at term, and
responses were negatively associated with z-FEV1 (p<0.001) in both groups (test of interaction,
p = 0.24).
There was no effect of neonatal BPD vs. no BPD on any of the assessed lung function vari-
ables (non-significant interaction-terms). Lung function variables that differed between the
EP- and term-born groups were analyzed also by GA-category, and the deficits were numeri-
cally most pronounced for the GA-category28 weeks, although interaction terms were non-
significant (Table 4).
Lung function related to perinatal and background variables
For EP1999–2000, BW z-score was the only significant predictor of z-FEV1 at 11 years (B = 0.24;
p = 0.04; R2 = 0.10) in a regression model including the following perinatal variables: GA, BW
z-scores, days on ventilator, days on oxygen treatment, use of antenatal and postnatal cortico-
steroids, surfactant treatment and BPD vs. no-BPD. Applying the same model on the EP1991–
1992, BW z-scores similarly predicted z-FEV1 (B = 0.35; p = 0.02) in a final model; however,
including also days of oxygen (B = -0.011; p<0.001) and antenatal corticosteroids (B = 0.59;
p = 0.03) (R2 = 0.48, all three variables). Maternal smoking in pregnancy was not associated
with z-FEV1 at age 11. Regressing the background variables asthma ever, asthma medication
Table 4. Lung function variables reflecting airway flow before and after administration of salbutamol, and bronchial responsiveness to methacho-
line, in 11 year old children born preterm (EP) in 1999–2000, split by gestational age (GA) at birth.
Controls N = 54 GA  25 weeks N = 10 GA 26–27 weeks N = 36 GA  28 weeks N = 11
Gestational age (SD) weeks - 24.4 (0.5) 26.7 (0.5) 29.2 (1.0)
Birth weight (SD) grams - 741.2 (107) 904.1 (177) 770.1 (146)
BW z-scores (SD) - 0.09 (0.9) -0.54 (1.0) -2.46 (0.7) ***
No. with SGAa (% of group) 1 (10) 8 (22) 11 (100)
No. with BPD (% of group) - 8 (80) 20 (56) 3 (27) ***
FEV1 z -0.27 (-0.52, -0.01) -0.46 (-1.28, 0.37) -0.54 (-0.82, -0.27) -1.22 ** (-1.84, -0.59)
z-Post-β2 -0.07 (-0.34, 0.21) 0.05 (-1.04, 1.13) -0.41 (-0.82, 0.01) -0.67 (-1.29, -0.04)
FEV1/FVC z -0.30 (-0.54, -0.05) -0.13 (-0.98, 0.73) -0.82 * (-1.12, -0.52) -1.38 ** (-1.93, -0.83)
z- Post-β2 0.22 (0.00, 0.44) 0.39 (-0.39, 1.18) -0.23 (-0.58, 0.13) -0.31 (-0.89, 0.28)
FEF25–75 z -0.52 (-0.78, -0.27) -0.92 (-1.59, -0.25) -1.07 * (-1.37, -0.77) -1.78 ** (-2.34, -1.22)
z- Post-β2 0.06 (-0.20, 0.31) -0.07 (-0.88, 0.74) -0.58 (-0.91, 0.24) -0.50 (-1.17, 0.17)
DRS geometric mean 3.48 (2.21, 5.47) 3.58 (1.11, 14.19) 12.74 ** (6.95, 23.33) 38.54 ** (1.74, 85.31)
Figures are observed means (95% confidence intervals) split by GA categories for those lung function variables that differed between the EP and term-
born groups. For abbreviations, please see list. Interaction terms, testing if differences between EP and matched term-born controls were different over
the three GA categories, were non-significant for all variables. * p-values testing differences between EP-born subgroups, or (when possible) EP-born




a SGA = small for gestational age.
doi:10.1371/journal.pone.0144243.t004
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last 12 months, wheeze last 12 months, atopy and maternal smoking in pregnancy on z-FEV1
at age 11, revealed no significant associations for either EP or term-born in any birth-cohort.
Differences between EP1991–1992 and EP1999–2000
Paired differences between EP-born and matched term-controls for the inclusion periods
1991–1992 and 1999–2000 are given in Table 5 and illustrated in Figs 2 and 3. The differences
were significantly smaller for the variables z-FEV1, z-FVC and z-FEF25–75 and RV/TLC for the
group with BPD born in 1999–2000 compared to the group with BPD born in 1991–1992 (tests
of interaction). Adjusting these interaction terms for differences between the study periods
regarding GA, BW, days on ventilator and PDA management did not influence conclusions,
whereas the effect disappeared for z-FEV1 when surfactant and/or antenatal corticosteroids
were included in the model. Differences between EP-born without BPD and their matched
term-controls did not differ between two inclusion periods.
Discussion
This study showed that respiratory outcomes in mid-childhood were encouraging in children
born at extremely low GAs or BWs in 1999–2000. Still, the preterm born participants had
more small-airway obstruction and bronchial hyperresponsiveness than matched term-con-
trols, but static lung volumes, diffusing capacity and exhaled nitric oxide did not differ. Out-
come data were in most respects unrelated to BPD, and those born most immature did
surprisingly well. Compared to children born similarly preterm in the same region in 1991–
1992, lung function data were generally better, and particularly for those with neonatal BPD,
where significant improvements had occurred for important variables.
Strengths and limitations
The major strengths of this study were the population-based design with almost complete
attendance, and recruitment of matched control groups that followed a strict algorithm based
on the ‘next-born-subject’ principle, minimizing risks of selection bias. An age difference of
approximately one year at follow-up between the two birth-cohorts was adjusted for by refer-
ence equations or by statistical models. Potential bias introduced by a two-center design was
limited by statistical analyses performed according to the matched preterm versus term-born
structure. The algorithm for inclusion was based on a combined use of GA and BW, initially
preferred in 1991–1992 to ensure inclusion of all children perceived to be extremely immature
at birth. We continued this approach in 1999–2000, although changing the GA criterion from
<29 weeks to<28 weeks. Due to the inclusion criteria the data may not be generalizable to
subjects born extremely preterm in general. A diagnosis of BPD must reflect oxygen treatment
algorithms, which to some extent is subject to department policy. In this study, the same senior
neonatologists operated the same algorithms for oxygen supplementation in both inclusion
periods, making systematic changes unlikely. The study could not discriminate moderate from
severe BPD since oxygen treatment at 36 weeks GA was provided through low flow nasal can-
nulas without recording the exact fraction of inspired oxygen (FiO2) [3]. By nature, unfavour-
able events or conditions tend to be linked in neonatal intensive care medicine, often setting up
vicious circles that require treatments with long-term side effects. Observational statistical
models struggle with these scenarios due to collinearity between variables. To limit spurious
associations we therefore excluded the independent neonatal variable considered least mean-
ingful if a correlation coefficient was 0.7 in the same analysis. This situation calls for cautious
interpretation of regression models that aim to address statistical associations between such
variables and outcome. The study may be criticized for having few participants. Longitudinal
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studies over decades are by nature difficult to perform as demonstrated by the paucity of simi-
lar data. The power calculations indicate reasonable detection limits.
Lung function in the children born preterm in 1999–2000
The lung function abnormalities in the 11 year old children born preterm in 1999–2000 were
minor. FEV1 was mostly within normal limits and they had no signs of abnormal volume dis-
tribution or diffusing capacity for carbon monoxide. However, forced mid-expiratory flow
(FEF25–75) in the range of 75% predicted and significant methacholine hyperresponsiveness
indicate that small airway airflow limitation and bronchial abnormalities were still present.
Those born most immature did surprisingly well, in that lung function variables did not differ
significantly from those of the term-controls. Moreover, the presence of neonatal BPD was not
significantly associated with outcome, contrasting some [12, 32], and consistent with one pre-
vious study [11]. Most of the differences between preterm and term-born groups seemed to be
explained by the highest GA-category; i.e. basically SGA infants with GA28 weeks who were
included on the basis of BW<1000 gram, in whom significant airway obstruction and remark-
ably high bronchial hyperresponsiveness were observed. In adjusted regression models, BW z-
score was the only remaining neonatal variable associated with FEV1 at age 11. Thus, within
the frames of todays advanced NICU management, the paradigm that neonatal BPD or
extreme immaturity is inevitably linked to poor long-term pulmonary outcome may need to be
revised. However, statements regarding causal pathways for novel findings are bound to be
speculations within the frames of a study of this kind.
Interestingly, administration of salbutamol increased all airflow variables to within 0.5 z-
score of zero; i.e. clearly within normal limits. Salbutamol responses were negatively and
Table 5. Comparison of lung function indices in two cohorts of children born preterm in 1991–92 (EP1991–92) and in 1999–2000 (EP1999–2000).
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Figures are mean differences (95% confidence intervals) between EP born subgroups and their respective matched term-born control subjects. The units
are z-scores, except the ratio RV/TLC and the variable DRS where figures are differences in the dose response slope to methacholine. Positive figures
indicate higher z-scores for the control group or higher DRS for the EP-born group.
* Interaction terms, testing if differences between EP and matched term-born controls were different in the two study periods (1991–92 vs. 1999–2000)
were non-significant, except for the groups with neonatal BPD, for which p-values are given.
doi:10.1371/journal.pone.0144243.t005
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similarly associated with FEV1 in the EP-born and term-control group, further reducing the
group differences. Few subjects had salbutamol responses considered clinically significant
(12% from baseline) [30], and on average the responses did not differ between the EP- and
term-born group. The question to what extent airway obstruction after EP birth is a fixed or
reversible phenomenon therefore remains unanswered.
Pulmonary abnormalities after EP birth may clinically mimic pediatric asthma, and studies
have reported increased respiratory symptoms and more hospital admissions, particularly dur-
ing the first few years of life [33–35]. In this group of 11 year old children born EP in 1999–
2000, current respiratory symptoms and use of asthma medication were reassuringly rare, also
in those who were most immature at birth, contrasting some previous studies (8, 12, 36). Child-
hood asthma is generally characterized by eosinophilic airway inflammation (17), which may
be assessed by fractional exhaled nitric oxide (FeNO) (25), with extended FeNO analyses as a
new promising tool (26). We found that neither FeNO nor alveolar NO differed between the
preterm and term-born group, providing support for the notion that eosinophilic airway
inflammation is not involved in lung disease after EP birth (10, 37). However, active inflamma-
tory mechanisms may still be involved, and recent studies have indicated increased oxidative
stress in the respiratory system after EP birth, pathways this study was not set up to explore
(38, 39).
Some authors have expressed optimism regarding long-term pulmonary outcomes in chil-
dren who were born EP more recently [11, 36]. Kotecha et al. found in their review milder
Fig 2. Z-FEV1 in 11 year old term and preterm-born (EP) subjects born in 1991–92 and 1999–2000, EP-
born split by the presence of BPD.
doi:10.1371/journal.pone.0144243.g002
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impairments in FEV1 for preterm born children with neonatal BPD (defined by need of oxygen
treatment at 28 days of age) in recent compared to earlier studies [36]. However, two research
groups reported data indicating that respiratory abnormalities are still present after EP birth;
one regional study of children born at GA< 28 weeks or BW< 1000 grams in 1997 in the
state of Victoria, Australia [12, 32], and another based on the EPICure study of children born
atGA< 26 weeks in 1995 in the UK or Ireland [10, 32]. Both studies reported significantly
lower z-FEV1 and z-FEF25–75 in preterm compared to term-born children. The Australian
study [12] compared children born in 1997 with a group born in 1991–92, and found overall
airflow limitation in both groups, but for those with no history of neonatal BPD, the children
born in 1997 had better z-FEV1 and z-FVC than those born in 1991–92. In light of the possibil-
ity that more children at risk of unfavorable outcome may have survived in the most recent
cohort, this may be interpreted as a positive development. These findings are in line with ours,
although we found this positive development particularly evident in the group with neonatal
BPD. The EPICure study had more extreme inclusion criteria, with mean GA at birth almost
two weeks lower (24.9) and BW approximately 100 gram lower (750 gram) than the EP1999–
2000 cohort of our study, and also a higher rate of neonatal BPD; i.e. 70% compared to 50%.
They found no differences between preterm and term-born participants regarding FRC, TLC
and alveolar volume, which is comparable to our findings, but elevated RV/TLC and some
impairments in DLCO and DLCO/VA; differences that we did not see as clearly in our EP1999–
2000 cohort but resembling our findings at ten years of age in the EP1991–1992 cohort [16]. One
Fig 3. Z-FEF25–75 in 11 year old term and preterm-born (EP) subjects born in 1991–92 and 1999–2000,
EP-born split by the presence of BPD.
doi:10.1371/journal.pone.0144243.g003
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may speculate that more infants born at the limits of viability in the EPICure study may have
contributed to these differences in findings.
Comparing lung function of children born preterm in 1991–1992 and
1999–2000
There were significant improvements for z-FEV1 and other important lung function variables
from 1991–1992 to 1999–2000. This was particularly evident for the group of children with
neonatal BPD, who presumably had the most turbulent neonatal history. The interaction terms
used to assess these improvements were robust for adjustment for most perinatal variables,
except that use of antenatal corticosteroids and surfactant eliminated the improvements in z-
FEV1. Thus, statistical modeling of the dataset suggested that more extensive use of these
modalities may partly explain the observed improvement with time. However, a limitation that
applies to studies of this kind is that a variety of known and unknown influences of possible
significance for outcome cannot be accounted for in the applied regression models. Thus, more
and larger studies are required to resolve this issue.
The inclusion algorithms varied slightly between the two preterm-born cohorts. Despite
this, the two groups had fairly similar BWs and GAs, although with more SGA children
included in 1999–2000. More SGA children and more extreme criteria as regards GA in 1999–
2000 should theoretically lead to worse outcomes, whereas the opposite was in fact observed.
Thus, one may argue that this strengthens the notion that outcome did in fact improve for the
average infant born preterm during the 1990s.
The field of neonatal intensive care is in constant change, and it has been suggested that
pushing the limits of viability might have masked improvements in outcome [4], although
some recent studies have indicated otherwise [12, 37]. We have previously reported respiratory
health and lung function data for subjects born EP in the early 1980s and 1990s and suggested
improvements with time in groups without neonatal BPD [13]. The present study which also
included children born in this millennium, indicates that improvements has also occurred in
children with BPD, i.e. the infants with the most turbulent neonatal history.
Conclusion
Eleven year old children born at extremely low GAs or BWs in 1999–2000 had more small-air-
way obstruction and bronchial hyperresponsiveness than matched term-controls, but lung vol-
umes and diffusing capacity were similar. Outcome was mostly unrelated to BPD, and those
born most immature did surprisingly well. Compared to a group born similarly preterm in the
same region nearly one decade earlier, lung function was generally better, particularly after
neonatal BPD. The findings indicate that infants born preterm in this millennium may have
better pulmonary prognosis than previously assumed, and that BPD or extreme immaturity
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